AgPlenus Launches AI Model for Predicting Antifungal Potency
AgPlenus, a subsidiary of Evogene Ltd., announced in a press release the launch of its Antifungal Potency Predictor (APP), a machine learning model designed to estimate the antifungal potency of small molecules based on their chemical structures. The tool extends the ChemPass AI for Ag platform by forecasting biological efficacy before chemical synthesis and laboratory validation.
The APP model uses machine learning algorithms trained on curated datasets to predict antifungal activity in early research stages. This capability allows the prioritization of molecules more likely to succeed in biological testing, reducing the number of compounds that require experimental evaluation.
The model is expected to strengthen AgPlenus' internal fungicide pipeline, including the APTF-1 target aimed at combating diseases such as Septoria wheat blotch. It will also assist in developing treatments for additional pathogens, including Botrytis and Fusarium. AgPlenus and Evogene plan to continue developing predictive AI models for other biological attributes in crop protection research.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Plaid Launches AI Models for Credit, Fraud and Payment Risk
Phylo Launches Target Atlas for Drug Target Prioritization
Quotient Sciences and Acesion Apply AI to Atrial Fibrillation Drugs
Illumina releases SpliceAI2 for genetic variant research
Inductive Bio launches Beacon-2 to predict human drug doses
Daily AI Brief: the AI news that matters, in your inbox.